Abstract
There is growing evidence that proteolytic systems of microglia are closely associated with both their protective and cytotoxic roles in the central nervous system (CNS). Cathepsin E and cathepsin S have been shown to play important roles in the major histocompatibility complex (MHC) class II-mediated antigen presentation of microglia. On the other hand, proteasome is required for MHC class-I-mediated antigen presentation of microglia during viral and bacterial infections in the CNS. Several recent studies have suggested an involvement of cathepsin D and insulin-degrading enzyme in the clearance of amyloid-β peptides by microglia. Furthermore, attention has been also paid to the deleterious effects of proteases secreted from microglia. Besides having roles in the endosomal / lysosomal system, cathepsin S and cathepsin B secreted from microglia are also found to be responsible for microglia-induced tissue damage and neuronal death. Tissue-type plasminogen activator secreted from microglia also participates in neuronal death, an enhancement of N-methyl-D-aspartate receptor-mediated synaptic transmission, and an activation of microglia. Calpain has been demonstrated to play a pivotal role in the pathogenesis of multiple sclerosis by degrading myelin proteins extracellulary. Furthermore, matrix metalloproteases secreted from microglia contribute to the cerebrovascular diseases by degrading components of the basal lamina around the cerebral blood vessels. In this review, I have focused on the proteolytic systems that are associated with the protective and cytotoxic roles of microglia in the CNS. The understanding of proteolytic events mediated by microglial proteases may also aid in the development of protease inhibitors as the novel neuroprotective agents.
Keywords: microglia, protease, antigen presentation, neuronal death, inflammation
Current Neuropharmacology
Title: Microglial Proteases: Strategic Targets for Neuroprotective Agents
Volume: 1 Issue: 1
Author(s): Hiroshi Nakanishi
Affiliation:
Keywords: microglia, protease, antigen presentation, neuronal death, inflammation
Abstract: There is growing evidence that proteolytic systems of microglia are closely associated with both their protective and cytotoxic roles in the central nervous system (CNS). Cathepsin E and cathepsin S have been shown to play important roles in the major histocompatibility complex (MHC) class II-mediated antigen presentation of microglia. On the other hand, proteasome is required for MHC class-I-mediated antigen presentation of microglia during viral and bacterial infections in the CNS. Several recent studies have suggested an involvement of cathepsin D and insulin-degrading enzyme in the clearance of amyloid-β peptides by microglia. Furthermore, attention has been also paid to the deleterious effects of proteases secreted from microglia. Besides having roles in the endosomal / lysosomal system, cathepsin S and cathepsin B secreted from microglia are also found to be responsible for microglia-induced tissue damage and neuronal death. Tissue-type plasminogen activator secreted from microglia also participates in neuronal death, an enhancement of N-methyl-D-aspartate receptor-mediated synaptic transmission, and an activation of microglia. Calpain has been demonstrated to play a pivotal role in the pathogenesis of multiple sclerosis by degrading myelin proteins extracellulary. Furthermore, matrix metalloproteases secreted from microglia contribute to the cerebrovascular diseases by degrading components of the basal lamina around the cerebral blood vessels. In this review, I have focused on the proteolytic systems that are associated with the protective and cytotoxic roles of microglia in the CNS. The understanding of proteolytic events mediated by microglial proteases may also aid in the development of protease inhibitors as the novel neuroprotective agents.
Export Options
About this article
Cite this article as:
Nakanishi Hiroshi, Microglial Proteases: Strategic Targets for Neuroprotective Agents, Current Neuropharmacology 2003; 1 (1) . https://dx.doi.org/10.2174/1570159033360502
DOI https://dx.doi.org/10.2174/1570159033360502 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Anti-Inflammatory Effects of Antidepressants: Possibilities for Preventives Against Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry Natural Compounds and Plant Extracts as Therapeutics Against Chronic Inflammation in Alzheimer's Disease - A Translational Perspective
CNS & Neurological Disorders - Drug Targets A Possible Placental Factor for Preeclampsia: sFlt-1
Current Medicinal Chemistry Biomarkers in Silent Traumatic Brain Injury
Current Pharmaceutical Design subject Index To Volume 1
Current Drug Targets - CNS & Neurological Disorders Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry Kruppel-Like Factors 4 and 5: Unity in Diversity
Current Genomics Enhancing Topical Analgesic Administration: Review and Prospect for Transdermal and Transbuccal Drug Delivery Systems
Current Pharmaceutical Design Editorial (Thematic Issue: Neuroinflammation a Common Link in Neurodegenerative Neurological and Psychiatric Disorders)
Current Pharmaceutical Design Co-Treatment with Anthocyanins and Vitamin C Ameliorates Ethanol- Induced Neurodegeneration via Modulation of GABAB Receptor Signaling in the Adult Rat Brain
CNS & Neurological Disorders - Drug Targets Recent Patents on Exoskeletal Rehabilitation Robot for Upper Limb
Recent Patents on Mechanical Engineering Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors
Current Cancer Drug Targets Gender Related Issues in the Management of Heart Failure
Current Pharmaceutical Design Mechanisms of Neuropathic Pain
Current Medicinal Chemistry - Central Nervous System Agents Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study
Current Alzheimer Research Nanoparticle-Based Gene Therapy Intervention for Stroke Treatment: A Systematic Review
Current Gene Therapy Innate Immunity in Alzheimer’s Disease: A Complex Affair
CNS & Neurological Disorders - Drug Targets Dissecting the Biological Effects of Isoflurane through the Mechanistic Target of Rapamycin (mTOR) and microRNAs (miRNAs)
Current Neurovascular Research